Last mentioned: Mar 23, 2026
Litigation Notice
Pomerantz LLP issues first public alert regarding the class action filing against Boston Scientific.
Form 8-K Filing
BSX files notice with the SEC regarding 'Other Events' involving executive shifts and operational updates.
Q4 2025 Earnings
Company reports financial results and provides updated guidance on clinical timelines.
AVANT GUARD Trial Pause
Boston Scientific announces a pause in its FARAPULSE PFA trial, citing the need for data review.
Pomerantz LLP has initiated a class action investigation and filing against Boston Scientific Corporation (BSX), alleging the medical device giant made misleading statements regarding its clinical trials and business prospects. The litigation follows a period of heightened volatility for the company's cardiovascular portfolio, specifically concerning the FARAPULSE PFA system and recent trial adjustments.
This page surfaces every story mentioning Boston Scientific Corporation across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Boston Scientific Corporation was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |